Understanding the kinomic contributions to tyrosine kinase inhibitor resistance in triple negative breast cancer

被引：0
|
作者：
Lefebvre, Cory [1 ]
Litchfield, David [1 ]
Allan, Alison [1 ]
机构：
[1] Western Univ, London, ON, Canada
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.SABCS18-1282
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1282
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Pharmacogenomics of Tyrosine Kinase Inhibitor Resistance
    Cascorbi, I.
    [J]. PUBLIC HEALTH GENOMICS, 2016, 19 : 2 - 2
  • [32] The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib
    Maiello, Monica R.
    De Luca, Antonella
    Carotenuto, Adele
    Campiglio, Manuela
    Napolitano, Maria
    D'Alessio, Amelia
    Menard, Sylvie
    Normanno, Nicola
    [J]. CANCER RESEARCH, 2006, 66 (08)
  • [33] The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib
    Normanno, N
    De Luca, A
    Maiello, MR
    Campiglio, M
    Napolitano, M
    Mancino, M
    Carotenuto, A
    Viglietto, G
    Menard, S
    [J]. JOURNAL OF CELLULAR PHYSIOLOGY, 2006, 207 (02) : 420 - 427
  • [34] EGFR signaling promotes resistance to CHK1 inhibitor prexasertib in triple negative breast cancer
    Lee, Kevin J.
    Wright, Griffin
    Bryant, Hannah
    Wiggins, Leigh Ann
    Schuler, Michele
    Gassman, Natalie R.
    [J]. CANCER DRUG RESISTANCE, 2020, 3 (04) : 980 - 991
  • [35] PLK1 inhibition overcomes PARP inhibitor resistance in triple-negative breast cancer
    Siraj, Abdul K.
    Poyil, Pratheesh Kumar
    Padmaja, Divya
    Parvathareddy, Sandeep Kumar
    Alobaisi, Khadija
    Begum, Rafia
    Almalik, Osama
    Al-Dayel, Fouad
    Al-Kuraya, Khawla S.
    [J]. CANCER RESEARCH, 2024, 84 (06)
  • [36] Mimicking the evolution of doxorubicin resistance in triple negative breast cancer
    Pearson, Kashenya
    Everett, Terrence
    Rorie, Checo J.
    [J]. CANCER RESEARCH, 2022, 82 (10)
  • [37] Quercetin overcomes chemotherapy resistance in triple negative breast cancer
    Srinivasan, Asha
    Thangavel, Chellappagounder
    Liu, Yi
    Shoyele, Sunday
    Den, Robert B.
    Selvakumar, Ponniah
    Lakshmikuttyamma, Ashakumary
    [J]. CANCER RESEARCH, 2015, 75
  • [38] Antitumor activity of the novel multi-kinase inhibitor EC-70124 in triple negative breast cancer
    Dolores Cuenca-Lopez, Maria
    Serrano-Heras, Gemma
    Carlos Montero, Juan
    Corrales-Sanchez, Veronica
    Gomez-Juarez, Monica
    Jose Gascon-Escribano, Maria
    Carlos Morales, Jorge
    Voisin, Veronique
    Elena Nunez, Luz
    Moris, Francisco
    Bader, Gary D.
    Pandiella, Atanasio
    Ocana, Alberto
    [J]. ONCOTARGET, 2015, 6 (29) : 27923 - 27937
  • [39] Preclinical characterization of the novel TTK kinase inhibitor S81694 for the treatment of triple negative breast cancer
    Colombo, Riccardo
    Burbridge, Mike
    Rodriguez, Marianne
    Cantero, Frederique
    Caldarelli, Marina
    Giorgini, Maria Laura
    Sola, Francesco
    Ballinari, Dario
    Ciomei, Marina
    Bosotti, Roberta
    Montagnoli, Alessia
    Lsacchi, Antonella
    Donati, Daniele
    Galvani, Arturo
    [J]. CANCER RESEARCH, 2015, 75
  • [40] Protein kinase C inhibitor chelerythrine selectively inhibits proliferation of triple-negative breast cancer cells
    Wanjun Lin
    Jiajun Huang
    Zhongwen Yuan
    Senling Feng
    Ying Xie
    Wenzhe Ma
    [J]. Scientific Reports, 7
12345